An observational study in Pulmonary Arterial Hypertension (PAH), sponsored by AOP Orphan Pharmaceuticals AG. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by AOP Orphan Pharmaceuticals AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
TRESPECT is an international, multicenter, observational registry designed to describe the real-world use, effectiveness, and tolerability of parenteral treprostinil in adults with newly diagnosed pulmonary arterial hypertension (PAH). The registry will include patients who initiated subcutaneous or intravenous treprostinil within 12 months of PAH diagnosis.
Both retrospective and prospective data will be collected from routine clinical care. Data will include patient characteristics, PAH treatment patterns, treprostinil dosing and route of administration, functional status, exercise capacity, biomarkers, echocardiographic and hemodynamic parameters, clinical events, and adverse events. Participants will be followed for at least 36 months or until a registry termination criterion is met. The registry is expected to enroll approximately 100 to 300 patients across specialized PAH centers in several European countries.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
This study's planned enrollment of 300 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →AOP Orphan Pharmaceuticals AG is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The registry will include approximately 100-300 adult patients (≥18 years of age) with confirmed pulmonary arterial hypertension (PAH), classified as Group 1 according to the prevailing ESC/ERS guidelines, who initiated parenteral treprostinil administered subcutaneously or intravenously on or after January 1, 2024. Written informed consent will be required for prospective data collection and for retrospective medical chart review, as applicable under local regulations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with confirmed pulmonary arterial hypertension who initiated parenteral treprostinil administered by the subcutaneous or intravenous route within 12 months of PAH diagnosis. Treatment selection, route of administration, dosing, titration, concomitant PAH therapy, and clinical management are determined by the treating physician according to routine clinical practice. Clinical, treatment, safety, and outcome data are collected retrospectively and/or prospectively as part of this observational registry.
Drug: treprostinil
Parenteral treprostinil administered by continuous subcutaneous or intravenous infusion as part of routine clinical care. The decision to initiate treatment, route of administration, starting dose, dose titration, treatment duration, and use of concomitant PAH therapies are determined by the treating physician and are not assigned by the registry. Data on treatment initiation, doses at approximately 2 and 4 weeks, longitudinal dosing, route of administration, tolerability, local site reactions, pain, treatment changes, and clinical outcomes are collected during registry follow-up.
Also known as: Parenteral Treprostinil, Subcutaneous Treprostinil, Intravenous Treprostinil
Mean Change From Baseline in 6-Minute Walk Distance at Month 12
Mean change in 6-minute walk distance from baseline to Month 12. The 6-minute walk distance is measured in meters. A positive change indicates improvement in exercise capacity.
Time frame: Baseline and Month 12
Number and Percentage of Participants by Change in New York Heart Association Functional Class at Month 12
Number and percentage of participants whose New York Heart Association Functional Class improved, remained unchanged, or worsened from baseline to Month 12. Functional Class ranges from Class I to Class IV, with a higher class indicating greater functional limitation.
Time frame: Baseline and Month 12
Number and Percentage of Participants With Local Administration-Site Reactions During the First 12 Months
Number and percentage of participants experiencing at least one local administration-site reaction associated with subcutaneous or intravenous treprostinil application during the first 12 months after treatment initiation.
Time frame: From baseline through Month 12
Mean Local Pain Score During the First 12 Months
Local pain associated with parenteral treprostinil application will be assessed on a numerical rating scale from 0 to 10. Higher scores indicate greater pain.
Time frame: Baseline, Week 2, Week 4, Month 3, Month 6, Month 9, and Month 12
Mean Change From Baseline in N-Terminal Pro-B-Type Natriuretic Peptide at Month 12
Mean change in N-terminal pro-B-type natriuretic peptide concentration from baseline to Month 12.
Time frame: Baseline and Month 12
Mean Change From Baseline in B-Type Natriuretic Peptide at Month 12
Mean change in B-type natriuretic peptide concentration from baseline to Month 12.
Time frame: Baseline and Month 12
Overall survival
Overall survival is defined as the time from initiation of parenteral treprostinil to death from any cause.
Time frame: From initiation of parenteral treprostinil until death from any cause, assessed up to 36 months
Number and Percentage of Participants by Reason for Early Initiation of Parenteral Treprostinil
Number and percentage of participants in each documented category of clinical reason for initiating parenteral treprostinil within 12 months of PAH diagnosis, irrespective of baseline risk category.
Time frame: Baseline
Mean Parenteral Treprostinil Dose at each visit
Parenteral treprostinil dose will be summarized at each visit. Dose will be reported in the unit ng/kg/min.
Time frame: Baseline, Week 2, Week 4, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24, Month 30, and Month 36
Number and Percentage of Participants by Route of Parenteral Treprostinil Administration
Number and percentage of participants receiving parenteral treprostinil by subcutaneous or intravenous administration at each visit.
Time frame: Baseline, Week 2, Week 4, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24, Month 30, and Month 36
Number and Percentage of Participants Receiving Concomitant Pulmonary Arterial Hypertension Therapy
Number and percentage of participants receiving each recorded category of concomitant pulmonary arterial hypertension therapy.
Time frame: Baseline, Month 3, Month 6, Month 9, Month 12, Month 18, Month 24, Month 30, and Month 36
Time to First Composite Clinical Worsening Event
Time from initiation of parenteral treprostinil to the first occurrence of death from any cause, PAH-related hospitalization, or lung transplantation.
Time frame: From initiation of parenteral treprostinil until the first composite clinical worsening event, assessed up to 36 months
Number and Percentage of Participants With Adverse Events
Number and percentage of participants experiencing at least one adverse event during registry follow-up. Adverse events will be summarized by seriousness, severity, outcome, causal relationship to treprostinil, and action taken with treatment.
Time frame: From baseline through Month 36
No study locations are listed for this record.
Start is estimated for Jul 2026; primary completion for Dec 2029, 41 months later.
Of 85 observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 93. This study's planned 41 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
AOP Orphan Pharmaceuticals AG